NASDAQ · OKYO
OKYO Pharma Limited
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
Loading market information…
OTC · KMSTF · USD
Stock price
Quote as of Nov 20, 2025, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kadimastem Ltd’s quoted price sits in the lower half of its reported 52-week range, 64.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.50+$0.01 (+0.67%)
OKYO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 53.13% below the high.
$0.08$0.00 (0.0%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 87.52% below the high.
$3.75+$0.01 (+0.27%)
PharmChem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.78% below the high.
$0.00$0.00 (0.0%)
Yourgene Health Plc: Healthcare · Medical - Diagnostics & Research.
$2.74-$0.01 (-0.27%)
Organicell Regenerative Medicine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.01-$0.04 (-76.0%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 84.0% below the high.
$0.98$0.00 (0.0%)
American Hemp Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.82% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
